Prophylactic Prostaglandin E1 Prevent Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease of the Liver after Allogeneic Hematopoietic Stem Cell Transplantation

Background Prostglandin E1 (PGE1) was used to prevent sinusoidal obstruction/veno-occlusive disease (SOS/VOD) of the liver after allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. This study examined risk factors for SOS/VOD, the effect of prophylactic PGE1 and the survival rate at day +100 in patients undergoing allogeneic HSCT. Methods PGE1 was given in continuous intravenous infusion from day -7 to day 14 after allogeneic HSCT at a dose of 0.3 micrograms/kg/hour. The patients were studied according to the risk factors for SOS/VOD: diagnosis, intensification of the conditioning and previous liver abnormalities. The diagnosis of SOS/VOD was made on revised diagnosis and severity criteria for SOS/VOD in new classification from the European society for blood and marrow transplantation. One hundred twenty-five patients underwent allogenic HSCT between September 2010 and August 2019 and 103 were treated by PGE1 and 22 did not received it. Results The median age of including patients was 44 year-old (range, 18-66 year-old) and male was 63 patients (45.3%). Among 125 patients, four (3.2%) developed SOS/VOD. The actual incidence of SOS/VOD was 1.9% (two patients) in the PGE1 group and 9.6% (two patients) in the non PGE1 group (P Conclusion The prophylactic PGE1 treatment may decrease the incidence of SOS/VOD in patients by allogenic hematopoietic stem cell transplantation.